about
Anti diabetic effect of CL 316,243 (a β3-adrenergic agonist) by down regulation of tumour necrosis factor (TNF-α) expression.Synthesis and characterization of a novel chemically designed (Globo)3-DTPA-KLH antigen.Identification of Methionine Oxidation in Human Recombinant Erythropoietin by Mass Spectrometry: Comparative Isoform Distribution and Biological Activity Analysis.Novel imatinib-loaded silver nanoparticles for enhanced apoptosis of human breast cancer MCF-7 cells.Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity.Development of a Time and Cost Benefit Antibody Binding Test-Based Method for Determination of Rabies Vaccine Potency.Rational design of hyper-glycosylated interferon beta analogs: a computational strategy for glycoengineering.Evaluation of G2 Citric Acid-Based Dendrimer as an Adjuvant in Veterinary Rabies Vaccine.Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties.Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties.Camel Heavy Chain Polyclonal Antibody Raised Against Recombinant Murine Placental Growth Factor Expressed in Escherichia coli.Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technologyDevelopment and Characterization of Nanoliposomal Hydroxyurea Against BT-474 Breast Cancer CellsCytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin ASynergistic Anti-Staphylococcal Activity Of Niosomal Recombinant Lysostaphin-LL-37Computational design, structure refinement and molecular dynamics simulation of novel engineered serratiopeptidase analogsRational affinity enhancement of fragmented antibody by ligand-based affinity improvement approach
P50
Q34441030-EB14CBE9-72F0-433D-86A5-E9D94149DAFAQ34783335-2C39F3F8-A594-4DFD-8E79-324A9AEC66A3Q38616210-F4663AD4-3858-462D-8798-1FECE0ADB032Q38760702-F837F814-723C-4993-8FE2-BB8083C60F65Q39016168-2A0DC541-EDDA-4413-9C15-D24F53E246D1Q40366511-93E24FC1-1E7E-4010-B7E1-60A71CBB3D04Q41644886-5CD6CBE5-305C-4F57-B83C-64292FE483ECQ47554426-9FC0D152-3315-4204-AB06-21E2EFC0FF80Q47753474-CAE39F02-9107-4002-B5B6-25C6F6CFFCBAQ50216954-7AB3ED89-385C-4E3F-A113-283F36FC9643Q50590479-6F38C7FE-7415-4CBC-85A0-12BE41BA01A5Q64098003-5F82FC9D-FA74-4869-A14D-8E53AF8D6156Q89457941-354B4E99-7F45-42C2-A1F9-14FE8B17C8D5Q90443368-BB14C196-3619-447F-ADAF-BC9B1F7D7501Q92068266-1C4E06F6-F487-44C3-937C-8706043BE468Q93205839-1CF90C15-AC02-417C-9EE4-C84CFBCB8A07Q93218562-780FE1EB-0994-4AE3-A9AC-F1139A3AA317
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Reza Ahangari Cohan
@ast
Reza Ahangari Cohan
@en
Reza Ahangari Cohan
@es
Reza Ahangari Cohan
@sl
type
label
Reza Ahangari Cohan
@ast
Reza Ahangari Cohan
@en
Reza Ahangari Cohan
@es
Reza Ahangari Cohan
@sl
altLabel
Cohan RA
@en
prefLabel
Reza Ahangari Cohan
@ast
Reza Ahangari Cohan
@en
Reza Ahangari Cohan
@es
Reza Ahangari Cohan
@sl
P1053
L-9626-2017
P106
P1153
37030668500
P31
P3829
P496
0000-0002-0490-4184